Report
Valens Research

UAFRS vs As Reported Weekly Highlights - Asia - 2020 04 17

This week, Valens identified distortions and the corresponding adjustments to correct for those distortions for 002252:CHN, FLEX, and 603660:CHN.
Underlyings
Flex Ltd.

Flex is a provider of Sketch-to-Scale™ services that designs, engineers, manufactures, and supply chain services and solutions. Co. operates following segments: Communications & Enterprise Compute, which includes its telecom and networking business, server and storage platforms, and security appliance products; Consumer Technologies Group, which includes its consumer-related businesses in connected living and supply chain solutions; Industrial and Emerging Industries, which include energy and metering, semiconductor tools and capital equipment, and industrial automation and kiosks; and High Reliability Solutions, which include its medical, automotive, defense and aerospace businesses.

Shanghai RAAS Blood Products Co. Ltd. Class A

Shanghai Raas Blood Products Company Limited. Shanghai RAAS Blood Products Co., Ltd. is a China-based company principally engaged in the research and development, manufacture and distribution of blood products. The Company's main products include human albumin and human immunoglobulin for intravenous injection, human coagulation factors and others. The Company is also engaged in the distribution of Chinese medicine products and foods. The Company distributes its products within domestic market and to overseas markets.

Suzhou Keda Technology (A)

Provider
Valens Research
Valens Research

In 2009, just as the dust was settling from the last major equity and credit market crises, we launched a boutique research firm with the intention of breaking Wall Street’s biases and broken incentives:

  • GAAP and IFRS have failed to provide rules for reliable financial statement reporting
  • Stock analyst recommendations are not grounded in disciplined financial analysis
  • Credit agencies have been set up to grossly fail in their responsibilities to investors and the public markets
  • Utter lack of willingness of major research firms to employ the the most advanced forensic analysis available

We sought to provide investors and company analysts with a source of information that changed all that.
Many years later, our business model remains because little has changed on Wall Street.

  • Corporate credit ratings remain years behind the fundamental underpinnings of company performance
  • Stock analysts continue to make recommendations with deeply inherent biases
  • Research firms have failed to break down the walls between credit, equity, and macroeconomic research
  • The governing accounting bodies have created more leeway for mis-estimates and mis-classifications as financials have become unwieldy and overwhelming

The integrity of Valens Research is founded in our disciplined processes and analytics. No “star” analysts. No corporate advisory relationships. No-nonsense opinions and recommendations.

Analysts
Valens Research

Other Reports on these Companies
Other Reports from Valens Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch